- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Eastman Kodak Company's Molecular Imaging Systems group announced the introduction of KODAK X-SIGHT Imaging Agents, a novel line of imaging agents for in vivo molecular imaging applications.
Once attached to a molecule and injected into an organism, the X-SIGHT imaging agents will travel to the target ( such as a tumor or plaque ) and illuminate the region of interest when excited by the appropriate wavelength of fluorescent light. X-SIGHT imaging agents are biocompatible and non-cytotoxic, making them safe and translatable for research studies in areas such as oncology, cardiology, diabetes, and inflammation, to name a few. They deliver not only superior brightness, but also enhanced photostability allowing more time for image capture.
This new product line leverages Kodak's 50 years of dye chemistry and nanotechnology expertise, merging world-class dyes with a state-of-the-art nanoparticle construct. X-SIGHT imaging agents are uniquely designed to offer biocompatibility along with superior brightness, providing researchers an incredibly bright and robust platform for safely locating their target of interest in vivo.
Together with Kodak's In-Vivo Imaging Systems, the X-SIGHT Imaging Agent line further expands the breadth of leading-edge solutions offered from Kodak to the research community.
"The launch of X-SIGHT Imaging Agents, is a significant milestone toward offering our customers a complete solution of systems and agents to advance their research," commented Shahram Hejazi, PhD, General Manager of Kodak's Molecular Imaging Systems division. "This introduction strengthens our leadership in the molecular imaging arena as we move forward to bridge the gap between preclinical and clinical applications."
X-SIGHT imaging agents can be readily conjugated to a wide range of targeting molecules, including peptides and antibodies, and their proprietary design can accommodate higher payloads of such targets while allowing for longer circulation time. Furthermore, X-SIGHT imaging agents are available in several distinct fluorescent wavelengths, enabling multi-fluorescent in vivo imaging. While the X-SIGHT imaging agents have been optimized for Kodak's In-Vivo Imaging Systems, they are also compatible with other commercially available systems.
X-SIGHT imaging agents are currently available for preclinical use in the United States and will be launched worldwide in March. Kodak further plans to introduce additional imaging agents throughout the year.
About Kodak’s Molecular Imaging Systems Group
Eastman Kodak Company’s Molecular Imaging Systems group - part of Kodak’s Health Group - develops and markets high performance digital imaging systems, imaging agents, film and accessories for the life science research and drug discovery/development market segments.
For more information, please click here
1-877-747-4357, express code 7.
Outside of the United States, call +1-203-786-5657.
Copyright © Eastman Kodak CompanyIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New Generation of Graphene Reinforced Carbon Fibre Prepreg Products March 14th, 2016
New Generation of Graphene Reinforced Carbon Fibre Prepreg Products March 10th, 2016
PEN Inc. Announces Strategy to Broaden Clarity Branded Products Business February 4th, 2016
Graphenea increases capacity, reduces prices January 25th, 2016
Cooling graphene-based film close to pilot-scale production April 30th, 2016
Personal cooling units on the horizon April 29th, 2016
Exploring phosphorene, a promising new material April 29th, 2016
Are humans the new supercomputer?Today, people of all backgrounds can contribute to solving serious scientific problems by playing computer games. A Danish research group has extended the limits of quantum physics calculations and simultaneously blurred the boundaries between mac April 14th, 2016
UCLA nanoscientists engage shoppers in fun conversations March 8th, 2016
Risk Analysis Publishes Non-Animal Strategy to Assess Nanomaterials February 24th, 2016